Adult: 600 mg daily in 2-3 divided doses. Use the lowest effective dose for the shortest possible duration needed to control symptoms. Dosage and treatment recommendations may vary among countries or between individual products (refer to specific product guidelines). Elderly: Use the lowest effective dose for the shortest possible treatment duration.
Special Patient Group
Elderly patients with cardiac impairment: May reduce dose to 200 mg bid. Treatment recommendations may vary among countries or between individual products (refer to specific product guidelines).
Renal Impairment
Mild to moderate: Use the lowest effective dose for the shortest possible treatment duration. In elderly patients with mild to moderate impairment, dose may be reduced to 200 mg bid. Severe: Contraindicated. Treatment recommendations may vary among countries or between individual products (refer to specific product guidelines).
Hepatic Impairment
Mild to moderate: Use the lowest effective dose for the shortest possible treatment duration. In elderly patients with mild to moderate impairment, dose may be reduced to 200 mg bid. Severe: Contraindicated. Treatment recommendations may vary among countries or between individual products (refer to specific product guidelines).
Administration
Tiaprofenic acid Should be taken with food.
Contraindications
Hypersensitivity to tiaprofenic acid. History of hypersensitivity reactions (e.g. asthma, rhinitis, angioedema, urticaria) to aspirin or other NSAIDs; active or history of recurrent peptic ulcer or gastrointestinal haemorrhage (≥2 distinct episodes of proven ulceration or bleeding), history of gastrointestinal bleeding or perforation related to previous NSAID therapy; active bladder or prostatic disease or symptoms, history of recurrent urinary tract disorder; severe heart failure. Severe renal and hepatic impairment. Pregnancy (3rd trimester).
Special Precautions
Patient with history of gastrointestinal ulcer (especially if complicated with haemorrhage or perforation), history of gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease); coagulation disorder, intracranial haemorrhage, risk factors for CV disease (e.g. hyperlipidaemia, diabetes mellitus, smoking), mild to moderate CHF, uncontrolled hypertension, oedema, established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, history of hepatic insufficiency, SLE, mixed connective tissue disorders, other forms of asthma. Debilitated and dehydrated patients. Patients undergoing surgery or dental procedures. Consider discontinuation of tiaprofenic acid in women who have difficulties conceiving or are undergoing investigation of infertility. Avoid concomitant use with other NSAIDS (including COX-2 selective inhibitors) and high-dose salicylates. Mild to moderate renal and hepatic impairment. Elderly. Pregnancy (1st-2nd trimester) and lactation.
Adverse Reactions
Significant: Sodium and water retention with oedema, severe cystitis or other urinary tract symptoms (e.g. dysuria, urinary frequency, haematuria); renal papillary necrosis (prolonged use), renal failure; increased risk of arterial thrombotic events (e.g. MI, stroke); new-onset or worsening of hypertension; elevated transaminase; anaphylactoid reactions; may impair female fertility; increased risk of aseptic meningitis (in patients with SLE and mixed connective tissue disorders); may decrease platelet adhesion and aggregation; blurred or diminished vision; may increase risk of hyperkalaemia (particularly in patients at least 65 years of age or those who have diabetes or renal disease). Rarely, potentially severe blood dyscrasias (e.g. agranulocytosis, thrombocytopenia, aplastic anaemia). Ear and labyrinth disorders: Vertigo, tinnitus. Gastrointestinal disorders: Upper abdominal pain, nausea, vomiting, dyspepsia, diarrhoea, constipation, pancreatitis. Immune system disorders: Non-specific allergic reactions, angioedema. Investigations: Abnormal LFT. Nervous system disorders: Dizziness, headache, drowsiness. Renal and urinary disorders: Tubulointerstitial nephritis, nephrotic syndrome. Respiratory, thoracic and mediastinal disorders: Dyspnoea. Skin and subcutaneous tissue disorders: Rash, pruritus, urticaria, alopecia, photosensitivity reaction. Potentially Fatal: Gastrointestinal bleeding, ulceration or perforation; drug reaction with eosinophilia and systemic symptoms (DRESS); bronchospasm (in patients with aspirin-sensitive asthma). Rarely, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, severe hepatic reactions (e.g. fulminant hepatitis, hepatic failure).
Patient Counseling Information
This drug may cause dizziness, drowsiness, fatigue and blurred vision, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor CBC, occult blood loss, LFTs (periodically), renal function (e.g. urine output, BUN, creatinine), electrolytes; response to therapy (e.g. pain, range of motion, grip strength, mobility), inflammation. Observe for weight gain, signs of oedema, bleeding or bruising; signs and symptoms of gastrointestinal effects (e.g. abdominal pain, bleeding, dyspepsia); mental confusion or disorientation. Perform ophthalmic exams periodically (prolonged use); urinalysis and urine culture (if urinary symptoms occur).
Overdosage
Symptoms: Headache, nausea, vomiting, epigastric pain, gastrointestinal bleeding, diarrhoea (rare), disorientation, excitation, drowsiness, dizziness, tinnitus, fainting, convulsion (occasional), coma; in cases of significant poisoning, acute renal failure and liver damage may occur.
Management: Symptomatic and supportive treatment. Administer activated charcoal within 1 hour of ingesting a potentially toxic amount. Alternatively, gastric lavage may be performed in adults within 1 hour of ingestion. Ensure good urine output. Administer IV diazepam for frequent or prolonged convulsions. Closely monitor hepatic and renal function. Observe patient for at least 4 hours following ingestion of potentially toxic amount.
Drug Interactions
Increased risk of ulceration or bleeding with oral corticosteroids, anticoagulants (e.g. heparin, warfarin, ticlopidine, clopidogrel, dabigatran, apixaban, rivaroxaban, edoxaban), SSRIs, antiplatelet agents (e.g. aspirin), thrombolytics, nicorandil, pentoxifylline. May increase the plasma concentration of cardiac glycosides, lithium, methotrexate. Increased risk of nephrotoxicity with tacrolimus, ciclosporin, tenofovir disoproxil fumarate. Increased risk of haematological toxicity with zidovudine. May increase the risk of developing convulsion with quinolone antibiotics. May reduce the effects of antihypertensive agents (e.g. ACE inhibitors, angiotensin II receptor antagonists, β-blockers), diuretics, and mifepristone (avoid tiaprofenic acid for at least 8-12 days after mifepristone use). Decreased metabolism and elimination with probenecid. May inhibit the metabolism of sulfonylurea drugs. May decrease the elimination of aminoglycosides. Potentially Fatal: Increased risk of adverse effect (particularly upper gastrointestinal disorders) with other NSAIDs and high-dose salicylates.
Food Interaction
Delayed absorption with food.
Lab Interference
May result in false-positive aldosterone/renin ratio (ARR).
Action
Description: Mechanism of Action: Tiaprofenic acid is a propionic acid derivative that has antipyretic, analgesic and anti-inflammatory properties. It acts by reversibly inhibiting cyclooxygenase-1 and 2 (COX-1 and 2) enzymes resulting in reduced formation of prostaglandin precursors. Pharmacokinetics: Absorption: Rapidly absorbed from the gastrointestinal tract. Delayed absorption with food. Time to peak plasma concentration: 30-90 minutes. Distribution: Crosses the placenta and enters breast milk. Plasma protein binding: Approx 98%. Metabolism: Metabolised into inactive metabolites (minimal). Excretion: Via urine (50% as unchanged drug, <10% as metabolites). Elimination half-life: Approx 2 hours.
Chemical Structure
Tiaprofenic acid Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5468, Tiaprofenic Acid. https://pubchem.ncbi.nlm.nih.gov/compound/Tiaprofenic-Acid. Accessed Feb. 25, 2026.
Storage
Store below 25°C. Protect from light and high humidity.
Sign Out
Continue with Google